Henry Ford Hospital Selects ValiMed From CDEX For Medication Validation
ValiMed Verifies Compounded Medications and Doses and Validates Narcotic Returns
ROCKVILLE, MD & DETROIT, MI– March 16, 2006 –Henry Ford Hospital has selected the ValiMed system to perform end-product testing of compounded intravenous medications in its pharmacy departments, and validation of returned narcotics in its operating room suites and nursing units. The ValiMed medication verification system was developed by CDEX (CEXI.OB) to give clinicians a quick, cost effective, and simple tool to further ensure medication safety by verifying medications are correctly compounded.
Henry Ford is a 903-bed tertiary care hospital, education and research complex in Detroit. The hospital is recognized for clinical excellence and innovations in the fields of cardiology and cardiovascular surgery, neurology and neurosurgery, orthopaedics and rehabilitation, organ transplantation, and treatment for prostate, breast and lung cancers, among others. Its Emergency Department is a Level 1 trauma center. Henry Ford is the flagship hospital for Henry Ford Health System, whose mission is to improve human life through excellence in the science and art of health care and healing.
In a process that takes only seconds, ValiMed uses patent-pending technology to validate compounded doses of high-risk medications prior to dispensing. The solution creates an added level of safety in the medication dispensing process, and is also used to validate narcotic returns as well as identify counterfeit medications.
"At Henry Ford, our top priority is patient safety. The ValiMed product strengthens our dispensing process by adding another level of safety to ensure compounded medications are accurately verified and narcotic returns are properly handled in the pharmacy," said Ed Szandzik, Director of Pharmacy at Henry Ford Hospital.
"We are pleased to be working with Henry Ford Hospital, yet another nationally recognized healthcare organization that has chosen to deploy ValiMed," said Jim Griffin, CEO for CDEX. “Partners like Henry Ford are valuable as CDEX continues its strategic growth in the healthcare sector.”
The ValiMed by CDEX solution uses light energy and a library of unique spectral fingerprints to validate drugs in solution. The device validates that the correct drugs in the correct amounts have been added to the dose during the compounding process.
About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is one line of CDEX products for the healthcare market. CDEX is headquartered in Rockville, Maryland with its research and development laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com.
Any statements made in this press release which contain information that is not historical are essentially forward-looking. Forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, the ability of the Company to raise capital to finance the development of its chemical detection products, the effectiveness, profitability and the marketability of those products, the ability of the Company to protect its proprietary information, the establishment of an efficient corporate operating structure as the Company grows and, other risks detailed from time-to-time in our filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statements.
Media Contact:
Brad Wills
Wills & Associates, Inc.
t. 301-767-1919
m. 301-346-7398
bwills@wills-pr.com
